Showing 1981-1990 of 2123 results for "".
- Higher Rates of COVID-19 Infection and Death for People With Parkinson Diseasehttps://practicalneurology.com/news/higher-rates-of-covid-19-infection-and-death-for-people-with-parkinson-disease/2469246/A paper accepted for publication in Movement Disorders suggests that people with Parkinson disease (PD) with longer disease duration (mean 12.7 years) may be more susceptible to infection with the SARS-CoV2 virus (COVID-19). Individual
- Risdiplam Resulted in Sitting Without Support for 5 Seconds by Month 12 for Infants with SMAhttps://practicalneurology.com/news/risdiplam-resulted-in-sitting-without-support-for-5-seconds-by-month-12-for-infants-with-sma/2469243/At the 1-year point of the Firefish part 2 (NCT02913482), a pivotal global study evaluating risdiplam (Genentech, San Francisco, CA), 29% (12/41; P<.0001) of infants with spinal muscular a
- FDA Approves Selumetinib for Children with Neurofibromatosis Type 1https://practicalneurology.com/news/fda-approves-selumetinib-for-children-with-neurofibromatosis-type-1/2469227/The Food and Drug Administration (FDA) approved selumetinib (Koselugo; AstraZeneca, Wilmington, DE) for the treatment of children age 2 years or more who have neurofibromatosis type 1 (NF1). Selumetinib, a kinase inhibitor, is approved for treatment of symptomatic inoperable plexiform neurofibrom
- Long-Term Exposure to Air Pollution and Rate of Cognitive Declinehttps://practicalneurology.com/news/long-term-exposure-to-air-pollution-and-rate-of-cognitive-decline/2469226/In a study published in Neurology researchers found an association of air pollution levels with cognitive impairment and decline in 1 of 2 large groups but not both. Both groups were ethnically and racially diverse and lived in the Northern Manhattan area of New York City. Participant's resid
- Rimegepant, Recently Approved for Acute Migraine Treatment, Now Available to Prescribe Via Telemedicinehttps://practicalneurology.com/news/rimegepant-recently-approved-for-acute-migraine-treatment-now-available-to-prescribe-via-telemedicine/2469221/Rimegepant (Nurtec; Biohaven, New Haven, CT), which was recently approved for acute treatment of migraine, is now available to be prescribed via a telemedicine platform (Cove, New York, NY). This is especially important in this unprecedented time of decreased access to routine health care, d
- FDA Authorizes Prescription Digital Therapeutic for Chronic Insomniahttps://practicalneurology.com/news/fda-authorizes-prescription-digital-therapeutic-for-chronic-insomnia/2469211/The Food and Drug Administration (FDA) has granted authorization for a prescription digital therapeutic (PDT) (Somryst, Pear Therapeutics, Boston, MA) intended for treating individuals age 22 years or more with chronic insomnia. The therapy is a 9-week PDT that can be used on a mo
- FDA Approves Ozanimod for Relapsing Multiple Sclerosishttps://practicalneurology.com/news/fda-approves-ozanimod-for-relapsing-multiple-sclerosis/2469208/The Food and Drug Administration (FDA) approved ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
- Investigational Nonsteroidal Edaslonexent Treatment for Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/investigational-nonsteroidal-edaslonexent-treatment-for-duchenne-muscular-dystrophy/2469205/Treatment of boys with Duchenne Muscular Dystrophy (DMD), age 4 to 7 years and never been exposed to steroids (n=31), led to growth patterns that were similar to children without DMD. Although the boys' growth rates were age normative, weight increase was less than the mean for boys at this a
- Head Sensors to Measure Frequency and Severity of Head Impact Have High Rate of False Positiveshttps://practicalneurology.com/news/head-sensors-to-measure-frequency-and-severity-of-head-impact-have-high-rate-of-false-positives/2469187/Concussion risk in young athletes has prompted researchers to use a variety of head impact sensors to measure frequency and severity of impacts during sports. A new study from Children's Hospital of Philadelphia (CHOP) shows these head sensors can record a large number of false positive impac
- Daytime Sleepiness in People Over Age 65 May Be at Risk for Medical Conditionshttps://practicalneurology.com/news/daytime-sleepiness-in-people-over-age-65-may-be-at-risk-for-medical-conditions/2469179/According to a preliminary study, people over age 65 who experience daytime sleepiness may be at risk of developing medical conditions such as diabetes, cancer, and high blood pressure. The study involved 10,930 participants and researchers interviewed participants over the phone twice, 3 years a